Browsing Radiotherapy and Imaging by author "Harrington, Kevin"
Now showing items 21-40 of 158
-
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison, ML; Blumenschein, G; Fayette, J; Guigay, J; Colevas, AD; et al. (WILEY, 2018-09-01)Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) ... -
CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Barker, HE; Patel, R; McLaughlin, M; Schick, U; Zaidi, S; et al. (AMER ASSOC CANCER RESEARCH, 2016-09-01)Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer-related deaths, with increasingly more cases arising due to high-risk human papillomavirus (HPV) infection. Cisplatin-based chemoradiotherapy is a ... -
Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
Allin, DM; Shaikh, R; Carter, P; Thway, K; Sharabiani, MTA; et al. (ELSEVIER SCI LTD, 2018-11-01)BACKGROUND: Conventional biomarkers in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful biomarker in ... -
Clinical development of new drug-radiotherapy combinations.
Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; et al. (NATURE PUBLISHING GROUP, 2016-10-01)In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ... -
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu, M; Armstrong, EJL; Jennings, V; Foo, S; Crespo-Rodriguez, E; et al. (TAYLOR & FRANCIS LTD, 2020-06-02)Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ... -
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.
Rajani, K; Parrish, C; Kottke, T; Thompson, J; Zaidi, S; et al. (CELL PRESS, 2016-01-01)Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical models and in early phase clinical trials. Reovirus has direct oncolytic activity against a variety of tumor types and antitumor ... -
Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.
Hafsi, H; Dillon, MT; Barker, HE; Kyula, JN; Schick, U; et al. (FRONTIERS MEDIA SA, 2018-07-13)Head and neck squamous cell carcinoma (HNSCC) is a significant cause of cancer deaths. Cisplatin-based chemoradiotherapy is a standard of care for locally advanced disease. ATR and DNA-PK inhibition (DNA-PKi) are actively ... -
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez, E; Bergerhoff, K; Bozhanova, G; Foo, S; Patin, EC; et al. (BMJ PUBLISHING GROUP, 2020-01-01)BACKGROUND: The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%-60% ... -
Combining Molecularly Targeted Agents: Is More Always Better?
Sundar, R; Valeri, N; Harrington, KJ; Yap, TA (AMER ASSOC CANCER RESEARCH, 2017-03-01)The concurrent targeting of critical nodes along key signaling pathways with molecularly targeted agents is a rational antitumor strategy, which has had varying degrees of success. Combinatorial challenges include overcoming ... -
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
Emancipator, K; Huang, L; Aurora-Garg, D; Bal, T; Cohen, EEW; et al. (ELSEVIER SCIENCE INC, 2020-11-25)Tumor proportion score (TPS) and combined positive score ([CPS] includes immune cells), 2 methods for scoring programmed death ligand 1 (PD-L1) expression, have been used in clinical trials investigating the immune checkpoint ... -
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Galluzzi, L; Vitale, I; Warren, S; Adjemian, S; Agostinis, P; et al. (BMJ PUBLISHING GROUP, 2020-01-01)Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple ... -
Contrast enhancement of carotid adventitial vasa vasorum as a biomarker of radiation-induced atherosclerosis.
Gujral, DM; Cheung, WK; Shah, BN; Chahal, NS; Bhattacharyya, S; et al. (ELSEVIER IRELAND LTD, 2016-07-01)PURPOSE: Abnormal proliferation of adventitial vasa vasorum (vv) occurs early at sites of atherosclerosis and is thought to be an early biomarker of vascular damage. Contrast-enhanced ultrasound (CEUS) can detect this ... -
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad, R; Cohen, EEW; Venkatachalam, M; Young, K; Singh, P; et al. (TAYLOR & FRANCIS LTD, 2020-05-03)Aim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US.Methods: We constructed a cohort-based partitioned survival model ... -
COSTAR trial results: 3-D Conformal Radiotherapy vs Cochlea-Sparing IMRT in parotid cancer patients
Nutting, C; Morden, J; Beasley, M; Bhide, S; Emson, M; et al. (ELSEVIER IRELAND LTD, 2017-03-01) -
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
Quinn, C; Garrison, LP; Pownell, AK; Atkins, MB; de Pouvourville, G; et al. (BMJ PUBLISHING GROUP, 2020-01-01)Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient's immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and ... -
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka, RHI; Agarwala, SS; Ollila, DW; Hallmeyer, S; Milhem, M; et al. (WILEY, 2016-12-01)BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic ... -
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar, I; Rooney, K; Roe, JWG; Patterson, JM; Bernstein, D; et al. (BMC, 2016-10-06)BACKGROUND: Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients' quality of life. Single arm studies have shown that the dosimetric sparing of ... -
Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.
Bhide, SA; Thway, K; Lee, J; Wong, K; Clarke, P; et al. (NATURE PUBLISHING GROUP, 2016-09-27)INTRODUCTION: The aim of this study was to investigate if defective repair of DNA double-strand break (DSB) in head and neck squamous cell carcinoma (HNSCC) could be used as an early predictor of treatment response. METHODS: ... -
Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams).
Grønhøj, C; Jensen, DH; Dehlendorff, C; Marklund, L; Wagner, S; et al. (SPRINGERNATURE, 2018-06-01)BACKGROUND: The proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system, but due to incongruence between p16 status and HPV infection, single biomarker evaluation could ... -
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas, S; Kuncheria, L; Roulstone, V; Kyula, JN; Mansfield, D; et al. (BMJ PUBLISHING GROUP, 2019-08-10)BACKGROUND: Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development ...